Alan L. Ho, MD, PhD, discusses an upcoming phase 3 trial evaluating Oz-V in OPSCC and key aspects of its design.
Alan L. Ho, MD, PhD
Advertisement
Alan L. Ho, MD, PhD, is chief of the Head and Neck Oncology Service and an attending physician at Memorial Sloan Kettering Cancer Center
Articles by Alan L. Ho, MD, PhD
Alan L. Ho, MD, PhD, discusses next steps for the evaluation of Oz-V in OPSCC based on its phase 2 efficacy in patients with treatment-refractory disease.
Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.
Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
4
Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC
5